Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Wondering whether Gilead Sciences at US$128.84 is offering you good value right now, or if most of the upside is already ...

Anthropic is launching Claude for Life Sciences, a new model aimed at aiding scientific research. Through integrations with leading life sciences players, the platform will help researchers at every ...

Abbott (ABT) stock dips as the company trims 2026 EPS guidance to reflect its recent $21B acquisition of Exact Sciences. Read more here.

The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...

The subject area represents the next stage of the database’s evolution, and heralds other proposed changes to journal selection and article categorization. The first Nature Index tables in the applied ...